Pharma Phriday (March 27, 2026): Advances in obesity, diabetes, and rare neuromuscular disease; new approvals in lymphoma, paediatrics, ophthalmology, and obesity; major acquisitions in haematology and autoimmune; and licensing deals for T-cell engagers, oncology, subQ delivery, and AI.

In Part 1 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how cost discipline, manufacturing shifts, and portfolio resets are reshaping large pharma.